The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application

Biomaterials

Volumn 33, Issue 9, 2012, Pages 2656-2672

  Zhang, Zhi Yong ^a   Teoh, Swee Hin ^a   Hui, James H P ^b   Fisk, Nicholas M ^c   Choolani, Mahesh ^d   Chan, Jerry K Y ^c,d,e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Bioreactor; Bone tissue engineering; Mesenchcymal stem cells; Scaffold

Indexed keywords

BONE TISSUE ENGINEERING; CELL SOURCES; CLINICAL TRIAL; CLINICAL USAGE; FRACTURE HEALING; IMMUNOGENECITY; IN-VIVO; LITERATURE REVIEWS; MACROPOROUS; MESENCHCYMAL STEM CELL; MESENCHYMAL STEM CELL; OSTEOGENESIS; OSTEOGENIC POTENTIAL; RECENT PROGRESS;

BIOREACTORS; BONE; CELL CULTURE; SCAFFOLDS; STEM CELLS; TISSUE;

SCAFFOLDS (BIOLOGY);

ANGIOPOIETIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR; TISSUE SCAFFOLD; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

BIOREACTOR; BONE DEVELOPMENT; BONE REMODELING; BONE TISSUE; CELL PROLIFERATION; CYTOLOGY; FRACTURE HEALING; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; MEDLINE; MESENCHYMAL STEM CELL; OSSIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STEM CELL NICHE; TISSUE ENGINEERING;

BONE AND BONES; CLINICAL TRIALS AS TOPIC; FETAL STEM CELLS; HUMANS; MESENCHYMAL STEM CELLS; TISSUE ENGINEERING;

EID: 84855918446     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.12.025     Document Type: Review

References (294)

1. Salgado A.J., Coutinho O.P., Reis R.L. Bone tissue engineering: state of the art and future trends. Macromol Biosci 2004, 4:743-765.
2. Marsh D. Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat Res 1998, S22-S30.
3. Banwart J.C., Asher M.A., Hassanein R.S. Iliac crest bone graft harvest donor site morbidity. a statistical evaluation. Spine 1995, 20:1055-1060.
4. Goulet J.A., Senunas L.E., DeSilva G.L., Greenfield M.L. Autogenous iliac crest bone graft. complications and functional assessment. Clin Orthop Relat Res 1997, 76-81.
5. Parikh S.N. Bone graft substitutes: past, present, future. JPostgrad Med 2002, 48:142-148.
6. Langer R., Vacanti J.P. Tissue engineering. Science 1993, 260:920-926.
7. Kimelman N., Pelled G., Helm G.A., Huard J., Schwarz E.M., Gazit D. Review: gene- and stem cell-based therapeutics for bone regeneration and repair. Tissue Eng 2007, 13:1135-1150.
8. Service R.F. Tissue engineers build new bone. Science 2000, 289:1498-1500.
9. Bruder S.P., Fox B.S. Tissue engineering of bone. cell based strategies. Clin Orthop Relat Res 1999, S68-S83.
10. Marsh D.R., Li G. The biology of fracture healing: optimising outcome. Br Med Bull 1999, 55:856-869.
11. Giannoudis P.V., Einhorn T.A., Marsh D. Fracture healing: a harmony of optimal biology and optimal fixation?. Injury 2007, 38(Suppl. 4):S1-S2.
12. Hollinger J.O., Brekke J., Gruskin E., Lee D. Role of bone substitutes. Clin Orthop Relat Res 1996, 55-65.
13. Rouwkema J., Rivron N.C., van Blitterswijk C.A. Vascularization in tissue engineering. Trends Biotechnol 2008, 26:434-441.
14. US-FDA FDA public health notification: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion 2008.
15. Hermann J.S., Buser D. Guided bone regeneration for dental implants. Curr Opin Periodontol 1996, 3:168-177.
16. Pioletti D.P., Montjovent M.O., Zambelli P.Y., Applegate L. Bone tissue engineering using foetal cell therapy. Swiss Med Wkly 2006, 136:557-560.
17. Logeart-Avramoglou D., Anagnostou F., Bizios R., Petite H. Engineering bone: challenges and obstacles. JCell Mol Med 2005, 9:72-84.
18. Connolly J.F., Guse R., Tiedeman J., Dehne R. Autologous marrow injection for delayed unions of the tibia: a preliminary report. JOrthop Trauma 1989, 3:276-282.
19. Caplan A.I. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 2005, 11:1198-1211.
20. Connolly J.F., Guse R., Tiedeman J., Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Relat Res 1991, 259-270.
21. Bruder S.P., Jaiswal N., Haynesworth S.E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. JCell Biochem 1997, 64:278-294.
22. Weissman I.L. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000, 287:1442-1446.
23. Okumura M., Ohgushi H., Dohi Y., Katuda T., Tamai S., Koerten H.K., et al. Osteoblastic phenotype expression on the surface of hydroxyapatite ceramics. JBiomed Mater Res 1997, 37:122-129.
24. Montjovent M.O., Burri N., Mark S., Federici E., Scaletta C., Zambelli P.Y., et al. Fetal bone cells for tissue engineering. Bone 2004, 35:1323-1333.
25. Karp J.M., Ferreira L.S., Khademhosseini A., Kwon A.H., Yeh J., Langer R.S. Cultivation of human embryonic stem cells without the embryoid body step enhances osteogenesis invitro. Stem Cells 2006, 24:835-843.
26. Robertson N.J., Brook F.A., Gardner R.L., Cobbold S.P., Waldmann H., Fairchild P.J. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A 2007, 104:20920-20925.
27. Kao C.L., Tai L.K., Chiou S.H., Chen Y.J., Lee K.H., Chou S.J., et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem Cells Dev 2010, 19:247-258.
28. Li F., Bronson S., Niyibizi C. Derivation of murine induced pluripotent stem cells (iPS) and assessment of their differentiation toward osteogenic lineage. JCell Biochem 2010, 109:643-652.
29. Grinnemo K.H., Sylven C., Hovatta O., Dellgren G., Corbascio M. Immunogenicity of human embryonic stem cells. Cell Tissue Res 2008, 331:67-78.
30. Swijnenburg R.J., Tanaka M., Vogel H., Baker J., Kofidis T., Gunawan F., et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005, 112:I166-I172.
31. Wu D.C., Boyd A.S., Wood K.J. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 2008, 26:1939-1950.
32. Charron D., Suberbielle-Boissel C., Al-Daccak R. Immunogenicity and allogenicity: a challenge of stem cell therapy. JCardiovasc Transl Res 2009, 2:130-138.
33. Drukker M., Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004, 22:136-141.
34. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
35. Draper J.S., Smith K., Gokhale P., Moore H.D., Maltby E., Johnson J., et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 2004, 22:53-54.
36. Spits C., Mateizel I., Geens M., Mertzanidou A., Staessen C., Vandeskelde Y., et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol 2008, 26:1361-1363.
37. Fong C.Y., Gauthaman K., Bongso A. Teratomas from pluripotent stem cells: a clinical hurdle. JCell Biochem 2010, 111:769-781.
38. Choo A.B., Tan H.L., Ang S.N., Fong W.J., Chin A., Lo J., et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008, 26:1454-1463.
39. Tan H.L., Fong W.J., Lee E.H., Yap M., Choo A. mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 2009, 27:1792-1801.
40. Tscheliessnig A., Ong D., Lee J., Pan S., Satianegara G., Schriebl K., et al. Engineering of a two-step purification strategy for a panel of monoclonal immunoglobulin M directed against undifferentiated human embryonic stem cells. JChromatogr A 2009, 1216:7851-7864.
41. Gentleman E., Swain R.J., Evans N.D., Boonrungsiman S., Jell G., Ball M.D., et al. Comparative materials differences revealed in engineered bone as a function of cell-specific differentiation. Nat Mater 2009, 8:763-770.
42. Dominici M., Le B.K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. the international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
43. Friedenstein A.J., Piatetzky S.I., Petrakova K.V. Osteogenesis in transplants of bone marrow cells. JEmbryol Exp Morphol 1966, 16:381-390.
44. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow. analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
45. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62.
46. Inoue K., Ohgushi H., Yoshikawa T., Okumura M., Sempuku T., Tamai S., et al. The effect of aging on bone formation in porous hydroxyapatite: biochemical and histological analysis. JBone Miner Res 1997, 12:989-994.
47. Kahn A., Gibbons R., Perkins S., Gazit D. Age-related bone loss. a hypothesis and initial assessment in mice. Clin Orthop Relat Res 1995, 69-75.
48. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
49. Miura M., Miura Y., Padilla-Nash H.M., Molinolo A.A., Fu B., Patel V., et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
50. Zhou Y.F., Bosch-Marce M., Okuyama H., Krishnamachary B., Kimura H., Zhang L., et al. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 2006, 66:10849-10854.
51. Aguilar S., Nye E., Chan J., Loebinger M., Spencer-Dene B., Fisk N., et al. Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 2007, 25:1586-1594.
52. Tasso R., Augello A., Carida M., Postiglione F., Tibiletti M.G., Bernasconi B., et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis 2009, 30:150-157.
53. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term invitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67:9142-9149.
54. Meza-Zepeda L.A., Noer A., Dahl J.A., Micci F., Myklebost O., Collas P. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. JCell Mol Med 2008, 12:553-563.
55. Sawada R., Ito T., Tsuchiya T. Changes in expression of genes related to cell proliferation in human mesenchymal stem cells during invitro culture in comparison with cancer cells. JArtif Organs 2006, 9:179-184.
56. Rubio D., Garcia S., De C.T., Paz M.F., Lloyd A.C., Bernad A., et al. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res 2008, 314:691-698.
57. Rubio D., Garcia S., Paz M.F., De C.T., Lopez-Fernandez L.A., Lloyd A.C., et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS One 2008, 3:e1398.
58. Rubio D., Garcia-Castro J., Martin M.C., de F.R., Cigudosa J.C., Lloyd A.C., et al. Spontaneous human adult stem cell transformation. Cancer Res 2005, 65:3035-3039.
59. Wang Y., Huso D.L., Harrington J., Kellner J., Jeong D.K., Turney J., et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005, 7:509-519.
60. Rosland G.V., Svendsen A., Torsvik A., Sobala E., McCormack E., Immervoll H., et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009, 69:5331-5339.
61. Retraction: spontaneous human adult stem cell transformation. Cancer Res 2010, 70:6682.
62. Garcia S., Bernad A., Martin M.C., Cigudosa J.C., Garcia-Castro J., de F.R. Pitfalls in spontaneous invitro transformation of human mesenchymal stem cells. Exp Cell Res 2010, 316:1648-1650.
63. Torsvik A., Rosland G.V., Svendsen A., Molven A., Immervoll H., McCormack E., et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res 2010, 70:6393-6396.
64. Kuo T.K., Ho J.H., Lee O.K. Mesenchymal stem cell therapy for nonmusculoskeletal diseases: emerging applications. Cell Transplant 2009, 18:1013-1028.
65. Friedenstein A.J., Latzinik N.W., Grosheva A.G., Gorskaya U.F. Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. Exp Hematol 1982, 10:217-227.
66. Phinney D.G., Kopen G., Righter W., Webster S., Tremain N., Prockop D.J. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. JCell Biochem 1999, 75:424-436.
67. Digirolamo C.M., Stokes D., Colter D., Phinney D.G., Class R., Prockop D.J. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999, 107:275-281.
68. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., et al. Tcell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. JBiomed Sci 2005, 12:47-57.
69. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
70. Newman R.E., Yoo D., LeRoux M.A., Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009, 8:110-123.
71. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
72. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation invitro and prolong skin graft survival invivo. Exp Hematol 2002, 30:42-48.
73. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
74. O D.K., Chan J., de F.J., Kennea N., Sandison A., Anderson J.R., et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet 2004, 364:179-182.
75. Khosrotehrani K., Johnson K.L., Cha D.H., Salomon R.N., Bianchi D.W. Transfer of fetal cells with multilineage potential to maternal tissue. JAMA 2004, 292:75-80.
76. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003, 5:485-489.
77. Caplan A.I. Mesenchymal stem cells. JOrthop Res 1991, 9:641-650.
78. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. JCell Physiol 2007, 213:341-347.
79. Woodbury D., Schwarz E.J., Prockop D.J., Black I.B. Adult rat and human bone marrow stromal cells differentiate into neurons. JNeurosci Res 2000, 61:364-370.
80. Zhao L.R., Duan W.M., Reyes M., Keene C.D., Verfaillie C.M., Low W.C. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002, 174:11-20.
81. Ong S.Y., Dai H., Leong K.W. Hepatic differentiation potential of commercially available human mesenchymal stem cells. Tissue Eng 2006, 12:3477-3485.
82. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Quinn G., et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007, 46:219-228.
83. Sgodda M., Aurich H., Kleist S., Aurich I., Konig S., Dollinger M.M., et al. Hepatocyte differentiation of mesenchymal stem cells from rat peritoneal adipose tissue invitro and invivo. Exp Cell Res 2007, 313:2875-2886.
84. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., et al. Mesenchymal stem cells can be differentiated into endothelial cells invitro. Stem Cells 2004, 22:377-384.
85. Gang E.J., Jeong J.A., Han S., Yan Q., Jeon C.J., Kim H. Invitro endothelial potential of human UC blood-derived mesenchymal stem cells. Cytotherapy 2006, 8:215-227.
86. Muraglia A., Cancedda R., Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate invitro according to a hierarchical model. JCell Sci 2000, 113(Pt 7):1161-1166.
87. Aubin J.E. Bone stem cells. JCell Biochem Suppl 1998, 30-31:73-82.
88. Aubin J.E. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001, 2:81-94.
89. Bruder S.P., Kurth A.A., Shea M., Hayes W.C., Jaiswal N., Kadiyala S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. JOrthop Res 1998, 16:155-162.
90. Meinel L., Betz O., Fajardo R., Hofmann S., Nazarian A., Cory E., et al. Silk based biomaterials to heal critical sized femur defects. Bone 2006, 39:922-931.
91. Bruder S.P., Kraus K.H., Goldberg V.M., Kadiyala S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. JBone Jt Surg Am 1998, 80:985-996.
92. Kruyt M.C., Dhert W.J., Yuan H., Wilson C.E., van B.C., Verbout A.J., et al. Bone tissue engineering in a critical size defect compared to ectopic implantations in the goat. JOrthop Res 2004, 22:544-551.
93. Bensaid W., Oudina K., Viateau V., Potier E., Bousson V., Blanchat C., et al. De novo reconstruction of functional bone by tissue engineering in the metatarsal sheep model. Tissue Eng 2005, 11:814-824.
94. Quarto R., Mastrogiacomo M., Cancedda R., Kutepov S.M., Mukhachev V., Lavroukov A., et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. NEngl J Med 2001, 344:385-386.
95. Cancedda R., Mastrogiacomo M., Bianchi G., Derubeis A., Muraglia A., Quarto R. Bone marrow stromal cells and their use in regenerating bone. Novartis Found Symp 2003, 249:133-143. 143-7, 170-4, 239-41.
96. Schimming R., Schmelzeisen R. Tissue-engineered bone for maxillary sinus augmentation. JOral Maxillofac Surg 2004, 62:724-729.
97. Bielby R., Jones E., McGonagle D. The role of mesenchymal stem cells in maintenance and repair of bone. Injury 2007, 38(Suppl. 1):S26-S32.
98. Yin D., Wang Z., Gao Q., Sundaresan R., Parrish C., Yang Q., et al. Determination of the fate and contribution of exvivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP. Mol Ther 2009, 17:1967-1978.
99. Yuan J., Zhang W.J., Liu G., Wei M., Qi Z.L., Liu W., et al. Repair of canine mandibular bone defects with bone marrow stromal cells and coral. Tissue Eng Part A 2010, 16:1385-1394.
100. Le A.X., Miclau T., Hu D., Helms J.A. Molecular aspects of healing in stabilized and non-stabilized fractures. JOrthop Res 2001, 19:78-84.
101. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. JCell Biochem 2003, 88:873-884.
102. Dimitriou R., Tsiridis E., Giannoudis P.V. Current concepts of molecular aspects of bone healing. Injury 2005, 36:1392-1404.
103. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
104. Snyder B.R., Chiu A.M., Prockop D.J., Chan A.W. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One 2010, 5:e9347.
105. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., Caplan A.I. Exvivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
106. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. JClin Oncol 2000, 18:307-316.
107. Shake J.G., Gruber P.J., Baumgartner W.A., Senechal G., Meyers J., Redmond J.M., et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002, 73:1919-1925.
108. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J 2006, 20:661-669.
109. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11:367-368.
110. Li Y., Chen J., Zhang C.L., Wang L., Lu D., Katakowski M., et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia 2005, 49:407-417.
111. Murphy J.M., Fink D.J., Hunziker E.B., Barry F.P. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003, 48:3464-3474.
112. Lange C., Togel F., Ittrich H., Clayton F., Nolte-Ernsting C., Zander A.R., et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005, 68:1613-1617.
113. Keilhoff G., Goihl A., Langnase K., Fansa H., Wolf G. Transdifferentiation of mesenchymal stem cells into Schwann cell-like myelinating cells. Eur J Cell Biol 2006, 85:11-24.
114. Prockop D.J., Kota D.J., Bazhanov N., Reger R.L. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). JCell Mol Med 2010, 14:2190-2199.
115. Horowitz M.C., Xi Y., Wilson K., Kacena M.A. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001, 12:9-18.
116. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000, 141:4768-4776.
117. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98:3527-3533.
118. Wu T., Bai H., Wang C.B., Zhang Q., Tantai L.F., Wang X.J., et al. Autologous bone marrow-derived mesenchymal stem cells and peripheral blood stem cells cotransplantation in treatment of hematological malignant diseases. Zhonghua Nei Ke Za Zhi 2009, 48:392-395.
119. Macmillan M.L., Blazar B.R., DeFor T.E., Wagner J.E. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009, 43:447-454.
120. Meuleman N., Tondreau T., Ahmad I., Kwan J., Crokaert F., Delforge A., et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 2009, 18:1247-1252.
121. Le B.K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
122. Ringden O., Labopin M., Gorin N.C., Le B.K., Rocha V., Gluckman E., et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the acute leukemia working party of the European group for blood and marrow transplantation. JClin Oncol 2004, 22:416-423.
123. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
124. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
125. Ball L.M., Bernardo M.E., Roelofs H., Lankester A., Cometa A., Egeler R.M., et al. Cotransplantation of exvivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
126. Le B.K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
127. Ning H., Yang F., Jiang M., Hu L., Feng K., Zhang J., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
128. Kebriaei P., Isola L., Bahceci E., Holland K., Rowley S., McGuirk J., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
129. Zhang L.S., Liu Q.F., Huang K., Zhang Y., Fan Z.P., Huang S.L. Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease. Zhonghua Nei Ke Za Zhi 2009, 48:542-546.
130. Zhou H., Guo M., Bian C., Sun Z., Yang Z., Zeng Y., et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010, 16:403-412.
131. Perico N., Casiraghi F., Introna M., Gotti E., Todeschini M., Cavinato R.A., et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilotstudy of safety and clinical feasibility. Clin J Am Soc Nephrol 2011, 6:412-422.
132. Garcia-Olmo D., Garcia-Arranz M., Herreros D., Pascual I., Peiro C., Rodriguez-Montes J.A. Aphase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005, 48:1416-1423.
133. Garcia-Olmo D., Herreros D., Pascual I., Pascual J.A., Del-Valle E., Zorrilla J., et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009, 52:79-86.
134. Duijvestein M., Vos A.C., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
135. Lazebnik L.B., Kniazev O.V., Konopliannikov A.G., Parfenov A.I., Ruchkina I.N., Mikhailova Z.F., et al. Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation. Eksp Klin Gastroenterol 2010, 3-15.
136. Sun L., Akiyama K., Zhang H., Yamaza T., Hou Y., Zhao S., et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27:1421-1432.
137. Liang J., Zhang H., Hua B., Wang H., Lu L., Shi S., et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 69:1423-1429.
138. Chen S.L., Fang W.W., Qian J., Ye F., Liu Y.H., Shan S.J., et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004, 117:1443-1448.
139. Chen S.L., Fang W.W., Ye F., Liu Y.H., Qian J., Shan S.J., et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004, 94:92-95.
140. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
141. Lunde K., Solheim S., Aakhus S., Arnesen H., Abdelnoor M., Egeland T., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. NEngl J Med 2006, 355:1199-1209.
142. Meyer G.P., Wollert K.C., Lotz J., Steffens J., Lippolt P., Fichtner S., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294.
143. Yao K., Huang R.C., Ge L., Qian J.Y., Li Y.L., Xu S.K., et al. Observation on the safety: clinical trail on intracoronary autologous bone marrow mononuclear cells transplantation for acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34:577-581.
144. Mohyeddin-Bonab M., Mohamad-Hassani M.R., Alimoghaddam K., Sanatkar M., Gasemi M., Mirkhani H., et al. Autologous invitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med 2007, 10:467-473.
145. Ripa R.S., Haack-Sorensen M., Wang Y., Jorgensen E., Mortensen S., Bindslev L., et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the stem cells in myocardial infarction (STEMMI) trial. Circulation 2007, 116:I24-I30.
146. Guhathakurta S., Subramanyan U.R., Balasundari R., Das C.K., Madhusankar N., Cherian K.M. Stem cell experiments and initial clinical trial of cellular cardiomyoplasty. Asian Cardiovasc Thorac Ann 2009, 17:581-586.
147. Williams A.R., Trachtenberg B., Velazquez D.L., McNiece I., Altman P., Rouy D., et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011, 108:792-796.
148. Trachtenberg B., Velazquez D.L., Williams A.R., McNiece I., Fishman J., Nguyen K., et al. Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 2011, 161:487-493.
149. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. Arandomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. JAm Coll Cardiol 2009, 54:2277-2286.
150. Katritsis D.G., Sotiropoulou P.A., Karvouni E., Karabinos I., Korovesis S., Perez S.A., et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005, 65:321-329.
151. Katritsis D.G., Sotiropoulou P.A., Giazitzoglou E., Karvouni E., Papamichail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 2007, 9:167-171.
152. Lasala G.P., Silva J.A., Kusnick B.A., Minguell J.J. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a phase I study. Cardiovasc Revasc Med 2011, 12:29-34.
153. Arguero R., Careaga-Reyna G., Castano-Guerra R., Garrido-Garduno M.H., Magana-Serrano J.A., de J.N. Cellular autotransplantation for ischemic and idiopathic dilated cardiomyopathy. preliminary report. Arch Med Res 2006, 37:1010-1014.
154. Chen S., Liu Z., Tian N., Zhang J., Yei F., Duan B., et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. JInvasive Cardiol 2006, 18:552-556.
155. Wang J.A., Xie X.J., He H., Sun Y., Jiang J., Luo R.H., et al. Aprospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34:107-110.
156. Chen Y., Gao E.M., Gao C.Y., Xu Y., Huang K.J., Niu Z.M., et al. Effects of intracoronary autologous bone marrow mononuclear cells transplantation in patients with dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2008, 36:1087-1091.
157. Kirillov A.M., Fatkhudinov T., Dyachkov A.V., Koroteev A.V., Goldshtein D.V., Bochkov N.P. Transplantation of allogenic cells in the therapy of patients with dilated cardiomyopathy. Bull Exp Biol Med 2007, 144:635-639.
158. Friis T., Haack-Sorensen M., Mathiasen A.B., Ripa R.S., Kristoffersen U.S., Jorgensen E., et al. Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand Cardiovasc J 2011, 45:161-168.
159. Lasala G.P., Silva J.A., Gardner P.A., Minguell J.J. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 2010, 61:551-556.
160. Mazzini L., Fagioli F., Boccaletti R., Mareschi K., Oliveri G., Olivieri C., et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:158-161.
161. Mazzini L., Mareschi K., Ferrero I., Vassallo E., Oliveri G., Boccaletti R., et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res 2006, 28:523-526.
162. Mazzini L., Mareschi K., Ferrero I., Vassallo E., Oliveri G., Nasuelli N., et al. Stem cell treatment in amyotrophic lateral sclerosis. JNeurol Sci 2008, 265:78-83.
163. Mazzini L., Ferrero I., Luparello V., Rustichelli D., Gunetti M., Mareschi K., et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol 2010, 223:229-237.
164. Karussis D., Karageorgiou C., Vaknin-Dembinsky A., Gowda-Kurkalli B., Gomori J.M., Kassis I., et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67:1187-1194.
165. Mohyeddin B.M., Yazdanbakhsh S., Lotfi J., Alimoghaddom K., Talebian F., Hooshmand F., et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? report of a pilot study. Iran J Immunol 2007, 4:50-57.
166. Yamout B., Hourani R., Salti H., Barada W., El-Hajj T., Al-Kutoubi A., et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. JNeuroimmunol 2010, 227:185-189.
167. Connick P., Kolappan M., Patani R., Scott M.A., Crawley C., He X.L., et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011, 12:62.
168. Moviglia G.A., Fernandez V.R., Brizuela J.A., Saslavsky J., Vrsalovic F., Varela G., et al. Combined protocol of cell therapy for chronic spinal cord injury. report on the electrical and functional recovery of two patients. Cytotherapy 2006, 8:202-209.
169. Pal R., Venkataramana N.K., Bansal A., Balaraju S., Jan M., Chandra R., et al. Exvivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy 2009, 11:897-911.
170. Lee P.H., Kim J.W., Bang O.Y., Ahn Y.H., Joo I.S., Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008, 83:723-730.
171. Bang O.Y., Lee J.S., Lee P.H., Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005, 57:874-882.
172. Mendonca M.L., Freitas G.R., Silva S.A., Manfrim A., Falcao C.H., Gonzales C., et al. Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke. Arq Bras Cardiol 2006, 86:52-55.
173. Lee J.S., Hong J.M., Moon G.J., Lee P.H., Ahn Y.H., Bang O.Y. Along-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010, 28:1099-1106.
174. Zhang Z.X., Guan L.X., Zhang K., Zhang Q., Dai L.J. Acombined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 2008, 10:134-139.
175. Venkataramana N.K., Kumar S.K., Balaraju S., Radhakrishnan R.C., Bansal A., Dixit A., et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 2010, 155:62-70.
176. Vojtassak J., Danisovic L., Kubes M., Bakos D., Jarabek L., Ulicna M., et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett 2006, 27(Suppl. 2):134-137.
177. Falanga V., Iwamoto S., Chartier M., Yufit T., Butmarc J., Kouttab N., et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007, 13:1299-1312.
178. Dash N.R., Dash S.N., Routray P., Mohapatra S., Mohapatra P.C. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009, 12:359-366.
179. Mohamadnejad M., Alimoghaddam K., Mohyeddin-Bonab M., Bagheri M., Bashtar M., Ghanaati H., et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007, 10:459-466.
180. Kursova L.V., Konoplyannikov A.G., Pasov V.V., Ivanova I.N., Poluektova M.V., Konoplyannikova O.A. Possibilities for the use of autologous mesenchymal stem cells in the therapy of radiation-induced lung injuries. Bull Exp Biol Med 2009, 147:542-546.
181. Koc O.N., Day J., Nieder M., Gerson S.L., Lazarus H.M., Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.
182. Hou C., Wu X., Jin X. Autologous bone marrow stromal cells transplantation for the treatment of secondary arm lymphedema: a prospective controlled study in patients with breast cancer related lymphedema. Jpn J Clin Oncol 2008, 38:670-674.
183. Marcacci M., Kon E., Moukhachev V., Lavroukov A., Kutepov S., Quarto R., et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 2007, 13:947-955.
184. Kitoh H., Kitakoji T., Tsuchiya H., Mitsuyama H., Nakamura H., Katoh M., et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis-a preliminary result of three cases. Bone 2004, 35:892-898.
185. Hibi H., Yamada Y., Kagami H., Ueda M. Distraction osteogenesis assisted by tissue engineering in an irradiated mandible: a case report. Int J Oral Maxillofac Implants 2006, 21:141-147.
186. Kitoh H., Kitakoji T., Tsuchiya H., Katoh M., Ishiguro N. Distraction osteogenesis of the lower extremity in patients with achondroplasia/hypochondroplasia treated with transplantation of culture-expanded bone marrow cells and platelet-rich plasma. JPediatr Orthop 2007, 27:629-634.
187. Kitoh H., Kawasumi M., Kaneko H., Ishiguro N. Differential effects of culture-expanded bone marrow cells on the regeneration of bone between the femoral and the tibial lengthenings. JPediatr Orthop 2009, 29:643-649.
188. Kitoh H., Kitakoji T., Tsuchiya H., Katoh M., Ishiguro N. Transplantation of culture expanded bone marrow cells and platelet rich plasma in distraction osteogenesis of the long bones. Bone 2007, 40:522-528.
189. Dallari D., Savarino L., Stagni C., Cenni E., Cenacchi A., Fornasari P.M., et al. Enhanced tibial osteotomy healing with use of bone grafts supplemented with platelet gel or platelet gel and bone marrow stromal cells. JBone Jt Surg Am 2007, 89:2413-2420.
190. Zhang P., Gan Y.K., Tang J., Hao Y.Q., Wang Y., Sun Y.H., et al. Clinical study of lumbar fusion by hybrid construct of stem cells technique and biodegradable material. Zhonghua Wai Ke Za Zhi 2008, 46:493-496.
191. Gan Y., Dai K., Zhang P., Tang T., Zhu Z., Lu J. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 2008, 29:3973-3982.
192. Filho C.H., Kerkis I., Kerkis A., Tatsui N.H., da C.N., Bueno D.F., et al. Allogenous bone grafts improved by bone marrow stem cells and platelet growth factors: clinical case reports. Artif Organs 2007, 31:268-273.
193. Yamada Y., Ueda M., Hibi H., Nagasaka T. Translational research for injectable tissue-engineered bone regeneration using mesenchymal stem cells and platelet-rich plasma: from basic research to clinical case study. Cell Transplant 2004, 13:343-355.
194. Yamada Y., Ueda M., Naiki T., Nagasaka T. Tissue-engineered injectable bone regeneration for osseointegrated dental implants. Clin Oral Implants Res 2004, 15:589-597.
195. Ueda M., Yamada Y., Ozawa R., Okazaki Y. Clinical case reports of injectable tissue-engineered bone for alveolar augmentation with simultaneous implant placement. Int J Periodontics Restorative Dent 2005, 25:129-137.
196. Yamada Y., Ueda M., Hibi H., Baba S. Anovel approach to periodontal tissue regeneration with mesenchymal stem cells and platelet-rich plasma using tissue engineering technology: a clinical case report. Int J Periodontics Restorative Dent 2006, 26:363-369.
197. Meijer G.J., de B.J., Koole R., van B.C. Cell based bone tissue engineering in jaw defects. Biomaterials 2008, 29:3053-3061.
198. Shayesteh Y.S., Khojasteh A., Soleimani M., Alikhasi M., Khoshzaban A., Ahmadbeigi N. Sinus augmentation using human mesenchymal stem cells loaded into a beta-tricalcium phosphate/hydroxyapatite scaffold. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 106:203-209.
199. Ueda M., Yamada Y., Kagami H., Hibi H. Injectable bone applied for ridge augmentation and dental implant placement: human progress study. Implant Dent 2008, 17:82-90.
200. Gonshor A., McAllister B.S., Wallace S.S., Prasad H. Histologic and histomorphometric evaluation of an allograft stem cell-based matrix sinus augmentation procedure. Int J Oral Maxillofac Implants 2011, 26:123-131.
201. Yamada Y., Nakamura S., Ito K., Kohgo T., Hibi H., Nagasaka T., et al. Injectable tissue-engineered bone using autogenous bone marrow-derived stromal cells for maxillary sinus augmentation: clinical application report from a 2-6-year follow-up. Tissue Eng Part A 2008, 14:1699-1707.
202. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
203. Horwitz E.M., Prockop D.J., Gordon P.L., Koo W.W., Fitzpatrick L.A., Neel M.D., et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97:1227-1231.
204. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
205. Le Blanc K., Gotherstrom C., Ringden O., Hassan M., McMahon R., Horwitz E., et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79:1607-1614.
206. Centeno C.J., Busse D., Kisiday J., Keohan C., Freeman M., Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician 2008, 11:343-353.
207. Wakitani S., Mitsuoka T., Nakamura N., Toritsuka Y., Nakamura Y., Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant 2004, 13:595-600.
208. Wakitani S., Okabe T., Horibe S., Mitsuoka T., Saito M., Koyama T., et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. JTissue Eng Regen Med 2011, 5:146-150.
209. Davatchi F., Abdollahi B.S., Mohyeddin M., Shahram F., Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. preliminary report of four patients. Int J Rheum Dis 2011, 14:211-215.
210. Meijer G.J., de B.J., Koole R., van B.C. Cell-based bone tissue engineering. PLoS Med 2007, 4:e9.
211. Suzuki Y., Kim K.J., Kotake S., Itoh T. Stromal cell activity in bone marrow from the tibia and iliac crest of patients with rheumatoid arthritis. JBone Miner Metab 2001, 19:56-60.
212. Mueller S.M., Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. JCell Biochem 2001, 82:583-590.
213. Rodriguez J.P., Montecinos L., Rios S., Reyes P., Martinez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. JCell Biochem 2000, 79:557-565.
214. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228.
215. Halvorsen Y.D., Franklin D., Bond A.L., Hitt D.C., Auchter C., Boskey A.L., et al. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. Tissue Eng 2001, 7:729-741.
216. Zuk P.A., Zhu M., Ashjian P., De U.D., Huang J.I., Mizuno H., et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13:4279-4295.
217. Hattori H., Sato M., Masuoka K., Ishihara M., Kikuchi T., Matsui T., et al. Osteogenic potential of human adipose tissue-derived stromal cells as an alternative stem cell source. Cells Tissues Organs 2004, 178:2-12.
218. Halvorsen Y.C., Wilkison W.O., Gimble J.M. Adipose-derived stromal cells-their utility and potential in bone formation. Int J Obes Relat Metab Disord 2000, 24(Suppl. 4):S41-S44.
219. Dragoo J.L., Choi J.Y., Lieberman J.R., Huang J., Zuk P.A., Zhang J., et al. Bone induction by BMP-2 transduced stem cells derived from human fat. JOrthop Res 2003, 21:622-629.
220. Lee J.A., Parrett B.M., Conejero J.A., Laser J., Chen J., Kogon A.J., et al. Biological alchemy: engineering bone and fat from fat-derived stem cells. Ann Plast Surg 2003, 50:610-617.
221. Cowan C.M., Shi Y.Y., Aalami O.O., Chou Y.F., Mari C., Thomas R., et al. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat Biotechnol 2004, 22:560-567.
222. Nakahara H., Dennis J.E., Bruder S.P., Haynesworth S.E., Lennon D.P., Caplan A.I. Invitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp Cell Res 1991, 195:492-503.
223. Sakaguchi Y., Sekiya I., Yagishita K., Ichinose S., Shinomiya K., Muneta T. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood 2004, 104:2728-2735.
224. De B.C., Dell A.F., Tylzanowski P., Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001, 44:1928-1942.
225. Eghbali-Fatourechi G.Z., Lamsam J., Fraser D., Nagel D., Riggs B.L., Khosla S. Circulating osteoblast-lineage cells in humans. NEngl J Med 2005, 352:1959-1966.
226. Gronthos S., Brahim J., Li W., Fisher L.W., Cherman N., Boyde A., et al. Stem cell properties of human dental pulp stem cells. JDent Res 2002, 81:531-535.
227. Gronthos S., Mankani M., Brahim J., Robey P.G., Shi S. Postnatal human dental pulp stem cells (DPSCs) invitro and invivo. Proc Natl Acad Sci U S A 2000, 97:13625-13630.
228. Toma J.G., Akhavan M., Fernandes K.J., Barnabe-Heider F., Sadikot A., Kaplan D.R., et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001, 3:778-784.
229. Hida N., Nishiyama N., Miyoshi S., Kira S., Segawa K., Uyama T., et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 2008, 26:1695-1704.
230. Schwab K.E., Gargett C.E. Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium. Hum Reprod 2007, 22:2903-2911.
231. Jazedje T., Perin P.M., Czeresnia C.E., Maluf M., Halpern S., Secco M., et al. Human fallopian tube: a new source of multipotent adult mesenchymal stem cells discarded in surgical procedures. JTransl Med 2009, 7:46.
232. Cheng M.T., Yang H.W., Chen T.H., Lee O.K. Isolation and characterization of multipotent stem cells from human cruciate ligaments. Cell Prolif 2009, 42:448-460.
233. Da S.M.L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. JCell Sci 2006, 119:2204-2213.
234. Sarugaser R., Lickorish D., Baksh D., Hosseini M.M., Davies J.E. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005, 23:220-229.
235. Bieback K., Kern S., Kluter H., Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004, 22:625-634.
236. Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L., Chen T.H. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103:1669-1675.
237. De C.P., Bartsch G.J., Siddiqui M.M., Xu T., Santos C.C., Perin L., et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007, 25:100-106.
238. in't Anker P., Scherjon S.A., Kleijburg-van K.C., Noort W.A., Claas F.H., Willemze R., et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003, 102:1548-1549.
239. Campagnoli C., Roberts I.A., Kumar S., Bennett P.R., Bellantuono I., Fisk N.M. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98:2396-2402.
240. in't Anker P., Noort W.A., Scherjon S.A., Kleijburg-van K.C., Kruisselbrink A.B., van B.R., et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003, 88:845-852.
241. Almeida-Porada G., El S.D., Porada C., Zanjani E.D. Differentiative potential of human metanephric mesenchymal cells. Exp Hematol 2002, 30:1454-1462.
242. Zhao Z., Liao L., Cao Y., Jiang X., Zhao R.C. Establishment and properties of fetal dermis-derived mesenchymal stem cell lines: plasticity invitro and hematopoietic protection invivo. Bone Marrow Transplant 2005, 36:355-365.
243. Hu Y., Liao L., Wang Q., Ma L., Ma G., Jiang X., et al. Isolation and identification of mesenchymal stem cells from human fetal pancreas. JLab Clin Med 2003, 141:342-349.
244. Rzhaninova A.A., Gornostaeva S.N., Goldshtein D.V. Isolation and phenotypical characterization of mesenchymal stem cells from human fetal thymus. Bull Exp Biol Med 2005, 139:134-140.
245. Da S.M.L., Caplan A.I., Nardi N.B. In search of the invivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
246. Farrington-Rock C., Crofts N.J., Doherty M.J., Ashton B.A., Griffin-Jones C., Canfield A.E. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 2004, 110:2226-2232.
247. Alliot-Licht B., Bluteau G., Magne D., Lopez-Cazaux S., Lieubeau B., Daculsi G., et al. Dexamethasone stimulates differentiation of odontoblast-like cells in human dental pulp cultures. Cell Tissue Res 2005, 321:391-400.
248. Collett G.D., Canfield A.E. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res 2005, 96:930-938.
249. Caplan A.I. New era of cell-based orthopedic therapies. Tissue Eng Part B Rev 2009, 15:195-200.
250. Caplan A.I. Why are MSCs therapeutic? new data: new insight. JPathol 2009, 217:318-324.
251. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., et al. Aperivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
252. Feng J., Mantesso A., De Bari C., Nishiyama A., Sharpe P.T. Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci U S A 2011, 108:6503-6508.
253. Zhang Z.Y., Teoh S.H., Chong M.S., Schantz J.T., Fisk N.M., Choolani M.A., et al. Superior osteogenic capacity for bone tissue engineering of fetal compared to perinatal and adult mesenchymal stem cells. Stem Cells 2009, 27:126-137.
254. Baksh D., Yao R., Tuan R.S. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007, 25:1384-1392.
255. Guillot P.V., De B.C., Dell F., Kurata H., Polak J., Fisk N.M. Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. Differentiation 2008, 76.
256. Im G.I., Shin Y.W., Lee K.B. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells?. Osteoarthritis Cartilage 2005, 13:845-853.
257. Liu T.M., Martina M., Hutmacher D.W., Hui J.H., Lee E.H., Lim B. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 2007, 25:750-760.
258. Panepucci R.A., Siufi J.L., Silva W.A., Proto-Siquiera R., Neder L., Orellana M., et al. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 2004, 22:1263-1278.
259. Kim B.S., Lee C.C., Christensen J.E., Huser T.R., Chan J.W., Tarantal A.F. Growth, differentiation, and biochemical signatures of rhesus monkey mesenchymal stem cells. Stem Cells Dev 2008, 17:185-198.
260. Frost J., Monk D., Moschidou D., Guillot P.V., Stanier P., Minger S.L., et al. The effects of culture on genomic imprinting profiles in human embryonic and fetal mesenchymal stem cells. Epigenetics 2011, 6:52-62.
261. Britannica E. The new encyclopaedia Britannica, 2007 Edition 2007.
262. Gotherstrom C., Ringden O., Westgren M., Tammik C., Le B.K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003, 32:265-272.
263. Polkinghorne J. Review of the guidance on the research use of fetuses and fetal material 1989, HMSO, London, CM 762.
264. Rosser A.E., Dunnett S.B. Neural transplantation in patients with Huntington's disease. Cns Drugs 2003, 17:853-867.
265. Clarkson E.D. Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results. Drugs Aging 2001, 18:773-785.
266. Touraine J.L., Roncarolo M.G., Bacchetta R., Raudrant D., Rebaud A., Laplace S., et al. Fetal liver transplantation: biology and clinical results. Bone Marrow Transplant 1993, 11(Suppl. 1):119-122.
267. Hohlfeld J., de B.R., Hirt-Burri N., Chaubert P., Gerber S., Scaletta C., et al. Tissue engineered fetal skin constructs for paediatric burns. Lancet 2005, 366:840-842.
268. Chan J., O'Donoghue K., de F.J., Roberts I.A., Kumar S., Morgan J.E., et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells 2005, 23:93-102.
269. Poloni A., Rosini V., Mondini E., Maurizi G., Mancini S., Discepoli G., et al. Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy 2008, 10:690-697.
270. Portmann-Lanz C.B., Schoeberlein A., Huber A., Sager R., Malek A., Holzgreve W., et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006, 194:664-673.
271. Laurencin C.T., Ambrosio A.M., Borden M.D., Cooper J.A. Tissue engineering: orthopedic applications. Annu Rev Biomed Eng 1999, 1:19-46.
272. Agrawal C.M., Ray R.B. Biodegradable polymeric scaffolds for musculoskeletal tissue engineering. JBiomed Mater Res 2001, 55:141-150.
273. Hutmacher D.W., Schantz T., Zein I., Ng K.W., Teoh S.H., Tan K.C. Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. JBiomed Mater Res 2001, 55:203-216.
274. Zein I., Hutmacher D.W., Tan K.C., Teoh S.H. Fused deposition modeling of novel scaffold architectures for tissue engineering applications. Biomaterials 2002, 23:1169-1185.
275. Lam C.X., Hutmacher D.W., Schantz J.T., Woodruff M.A., Teoh S.H. Evaluation of polycaprolactone scaffold degradation for 6 months invitro and invivo. JBiomed Mater Res A 2008.
276. Schantz J.T., Hutmacher D.W., Chim H., Ng K.W., Lim T.C., Teoh S.H. Induction of ectopic bone formation by using human periosteal cells in combination with a novel scaffold technology. Cell Transplant 2002, 11:125-138.
277. Zhang Z.Y., Teoh S.H., Chong W.S., Foo T.T., Chng Y.C., Choolani M., et al. Abiaxial rotating bioreactor for the culture of fetal mesenchymal stem cells for bone tissue engineering. Biomaterials 2009, 30:2694-2704.
278. Rai B., Teoh S.H., Ho K.H., Hutmacher D.W., Cao T., Chen F., et al. The effect of rhBMP-2 on canine osteoblasts seeded onto 3D bioactive polycaprolactone scaffolds. Biomaterials 2004, 25:5499-5506.
279. Rai B., Ho K.H., Lei Y., Si-Hoe K.M., Jeremy T.C., Yacob K.B., et al. Polycaprolactone-20% tricalcium phosphate scaffolds in combination with platelet-rich plasma for the treatment of critical-sized defects of the mandible: a pilot study. JOral Maxillofac Surg 2007, 65:2195-2205.
280. Rai B., Oest M.E., Dupont K.M., Ho K.H., Teoh S.H., Guldberg R.E. Combination of platelet-rich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair. JBiomed Mater Res A 2007, 81:888-899.
281. Ishaug S.L., Crane G.M., Miller M.J., Yasko A.W., Yaszemski M.J., Mikos A.G. Bone formation by three-dimensional stromal osteoblast culture in biodegradable polymer scaffolds. JBiomed Mater Res 1997, 36:17-28.
282. Martin I., Obradovic B., Freed L.E., Vunjak-Novakovic G. Method for quantitative analysis of glycosaminoglycan distribution in cultured natural and engineered cartilage. Ann Biomed Eng 1999, 27:656-662.
283. Gomes M.E., Sikavitsas V.I., Behravesh E., Reis R.L., Mikos A.G. Effect of flow perfusion on the osteogenic differentiation of bone marrow stromal cells cultured on starch-based three-dimensional scaffolds. JBiomed Mater Res A 2003, 67:87-95.
284. Chen H.C., Hu Y.C. Bioreactors for tissue engineering. Biotechnol Lett 2006, 28:1415-1423.
285. Martin I., Wendt D., Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol 2004, 22:80-86.
286. Marolt D., Augst A., Freed L.E., Vepari C., Fajardo R., Patel N., et al. Bone and cartilage tissue constructs grown using human bone marrow stromal cells, silk scaffolds and rotating bioreactors. Biomaterials 2006, 27:6138-6149.
287. Stiehler M., Bunger C., Baatrup A., Lind M., Kassem M., Mygind T. Effect of dynamic 3-D culture on proliferation, distribution, and osteogenic differentiation of human mesenchymal stem cells. JBiomed Mater Res A 2008.
288. Sikavitsas V.I., Bancroft G.N., Mikos A.G. Formation of three-dimensional cell/polymer constructs for bone tissue engineering in a spinner flask and a rotating wall vessel bioreactor. JBiomed Mater Res 2002, 62:136-148.
289. Singh H., Ang E.S., Lim T.T., Hutmacher D.W. Flow modeling in a novel non-perfusion conical bioreactor. Biotechnol Bioeng 2007, 97:1291-1299.
290. Goldstein A.S., Juarez T.M., Helmke C.D., Gustin M.C., Mikos A.G. Effect of convection on osteoblastic cell growth and function in biodegradable polymer foam scaffolds. Biomaterials 2001, 22:1279-1288.
291. Bilodeau K., Mantovani D. Bioreactors for tissue engineering: focus on mechanical constraints. a comparative review. Tissue Eng 2006, 12:2367-2383.
292. Singh H., Teoh S.H., Low H.T., Hutmacher D.W. Flow modelling within a scaffold under the influence of uni-axial and bi-axial bioreactor rotation. JBiotechnol 2005, 119:181-196.
293. Zhang Z.Y., Teoh S.H., Teo E.Y., Khoon C.M., Shin C.W., Tien F.T., et al. Acomparison of bioreactors for culture of fetal mesenchymal stem cells for bone tissue engineering. Biomaterials 2010, 31:8684-8695.
294. Zhang Z.Y., Teoh S.H., Chong M.S., Lee E.S., Tan L.G., Mattar C.N., et al. Neo-vascularization and bone formation mediated by fetal mesenchymal stem cell tissue-engineered bone grafts in critical-size femoral defects. Biomaterials 2010, 31:608-620.